



LKT Laboratories, Inc.

BI-6727

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID B3300

CAS No. 755038-65-4

Chemical Name

Synonym BI6727, Volasertib

Formula $C_{34}H_{50}N_8O_3$

Formula Wt. 618.81

Melting Point


Purity $\geq 99\%$

Solubility DMSO 20 mg/mL warmed
(32.32 mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description BI-6727 is a polo-like kinase 1 (PLK1) inhibitor that exhibits anticancer activity. In vitro, BI-6727 induces apoptosis in acute myelogenous leukemia (AML) cells. This compound is currently in clinical trials as a potential treatment for several cancers; it improves response and survival rates.



Bulk quantities available upon request

Product ID	Size
B3300	1 mg
B3300	5 mg
B3300	10 mg

References Münch C, Dragoi D, Frey AV, et al. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. *Leuk Res.* 2015 Jan 28. [Epub ahead of print]. PMID: 25697066.

Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. *Leukemia.* 2015 Jan;29(1):11-9. PMID: 25027517.

Lin CC, Su WC, Yen CJ, et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. *Br J Cancer.* 2014 May 13;110(10):2434-40. PMID: 24755882.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.